Clinical Study

An Open-Label, Single-Arm Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Early Stage Relapsing Remitting Multiple Sclerosis

Posted Date: Jun 27, 2017

  • Investigator: Lawrence Goldstick
  • Co-Investigator: Samantha Maldonado
  • Specialties:
  • Type of Study: Observational/Survey

The purpose of this study is to see if ocrelizumab (study drug) will halt the worsening of the signs and symptoms of your early stage MS. Ocrelizumab is a type of drug called a monoclonal antibody. Monoclonal antibodies act like your body’s immune syst

Criteria:

You Are Invited To Take Part In A Research Study (Also Known As A Clinical Trial) Of A Drug Called Ocrelizumab. You Were Selected As A Possible Participant In This Study Because You Have Early Stage Relapsing Remitting Form Of Multiple Sclerosis (Ms).

Keywords:

Relapse Remitting, Monoclonal Antibodies, F. Hoffmann-La Roche Ltd, Multiple Sclerosis, Ocrelizumab

For More Information:

Samantha Maldonado
937-535-5012
samantha.maldonado@uchealth.com

  • Search Clinical Studies

  • Research in the News

    NIDA Director Nora Volkow to Speak on Opioid Crisis Nov. 27

    Nora Volkow, MD, director of the National Institute on Drug Abuse (NIDA), willbe the keynote speaker at a public symposium on tackling the opioid crisis onMonday, Nov. 27